EUROESPES, S.A. Inactive Instrument
Euroespes, S.A. Share Price BME
Equities
ES0133421000
Healthcare Facilities & Services
| Sales 2021 | 3.85M 4.18M 330M | Sales 2022 | 3.86M 4.18M 330M | Capitalization | 5.8M 6.28M 497M |
|---|---|---|---|---|---|
| Net income 2021 | - 0 0 | Net income 2022 | -1M -1.08M -85.72M | EV / Sales 2021 | 2.12 x |
| Net Debt 2021 | 2.08M 2.26M 179M | Net Debt 2022 | 3.46M 3.75M 296M | EV / Sales 2022 | 2.4 x |
| P/E ratio 2021 |
-32.9
x | P/E ratio 2022 |
-4.75
x | Employees | - |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 30.85% |
More Fundamentals
* Assessed data
More news
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 21/12/22 | |
| Corporate Secretary | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 62 | - | |
| Director/Board Member | - | - | |
| Director/Board Member | - | - |
Euroespes SA is a Spain-based company engaged in the healthcare sector. The Company operates a medical center, which focuses on the prevention, diagnosis and treatment of central nervous system disorders, such as Alzheimer and Parkinson, and other common diseases. The Companyâs medical offer includes personalized treatment plans, genomic medicine, epigenetics, neuropsychology, neuro-ophthalmology, digital diagnosis, diagnostic imaging, clinical analysis and nursing services, among others. In addition, it provides pharmacogenetics services and Human Identification Genetics card, which identifies user's deoxyribonucleic acid (DNA) profile. The Company operates through a number of subsidiaries, such as in Euroespes Biotecnologia SA, Distribuidora de Productos SL and Ebiotec Pharma SL.
| 1st Jan change | Capi. | |
|---|---|---|
| +19.22% | 84.52B | |
| -27.14% | 72.21B | |
| +4.65% | 27.74B | |
| -6.23% | 17.97B | |
| -0.21% | 17.46B | |
| +3.30% | 15.82B | |
| +7.44% | 13.55B | |
| +6.61% | 13.31B | |
| +73.32% | 13.32B |
